|
Psoriasis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.
|
26974007 |
2016 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.
|
26974007 |
2016 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
TNFRSF14 is known as herpes virus entry mediator (HVEM), and herpes viruses have been involved in the aetiology of multiple sclerosis (MS).
|
20962851 |
2011 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
Herpes virus entry mediator (HVEM) is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF14), which serves as a receptor for herpes viruses and cytokines such as lymphotoxin-alpha (LT-alpha) and LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for herpes virus entry on T cells).
|
19680232 |
2010 |
|
Herpes NOS
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
To determine cellular and temporal expression patterns of herpes virus entry mediator (HVEM, Tnfrsf14) in the murine cornea during the course of herpes simplex virus 1 (HSV-1) infection, the impact of this expression on pathogenesis, and whether alterations in HVEM or downstream HVEM-mediated effects ameliorate corneal disease.
|
28114589 |
2017 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
Overexpression of LIGHT (LIGHT: homologous to lymphotoxins, indicating inducible expression, and competes with herpes simplex virus glycoprotein D for herpes virus entry mediator [HVEM/TR2]) in MDA-MB-231 human breast cancer cells was observed to suppress tumor growth in vivo.
|
12651068 |
2003 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
The co-signaling molecule, LIGHT, is particularly well suited for use in vaccine development as it delivers a potent co-stimulatory signal through the Herpes virus entry mediator (HVEM) receptor on T cells and facilitates tumor-specific T cell immunity.
|
21877247 |
2012 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
Characterization of Sex Differences in Ocular Herpes Simplex Virus 1 Infection and Herpes Stromal Keratitis Pathogenesis of Wild-Type and Herpesvirus Entry Mediator Knockout Mice.
|
30918059 |
2019 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
One such gene, tumor necrosis factor receptor superfamily 14 (TNFRSF14), abnormal in 40% of FL patients, encodes the herpes virus entry mediator (HVEM) which limits T-cell activation via ligation of the B- and T-lymphocyte attenuator.
|
27103745 |
2016 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
We observed spontaneous osteoclastogenesis with a significant increase in OC formation and bone resorbing activity in late-stage CKD and HD patients when compared with early-stage CKD patients and healthy donors, likely due to an increased expression of RANKL and LIGHT (homologous to Lymphotoxins exhibiting Inducible expression and competing with herpes simplex virus Glycoprotein D for herpes virus entry mediator [HVEM], a receptor expressed by T lymphocytes) in PBMCs.
|
28992140 |
2018 |
|
Herpes NOS
|
0.090 |
Biomarker
|
disease |
BEFREE |
Using respiratory virus infection, we show that herpes virus entry mediator (HVEM; TNFRSF14), a member of the TNF receptor superfamily, provides key signals for MPEC persistence.
|
28864473 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Similarly, the high expression of HVEM was also significantly correlated with lymph node metastasis (<i>P</i>=0.007) and depth of invasion (<i>P</i>=0.011).
|
28243127 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
HVEM expression was found to be significantly correlated with depth of tumor invasion and lymph node metastasis.
|
24249528 |
2014 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
HVEM is highly expressed in ovarian serous adenocarcinoma tissues and correlated with the patient clinicopathological features, such as TNM staging, lymph node metastasis and recurrence.
|
28365939 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Our research also indicated an association between polymorphisms of HVEM and clinicopathologic features, including lymph node metastasis, estrogen receptor, progesterone receptor and P53.
|
23976978 |
2013 |
|
Systemic Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The cytokine TNFSF14 [homologous to Lymphotoxin, exhibits Inducible expression and competes with HSV Glycoprotein D for binding to HVEM, a receptor expressed on T lymphocytes (LIGHT)] has been shown in mouse models to be important for development of lung tissue remodeling that is characteristic of asthma, idiopathic pulmonary fibrosis (IPF), and systemic sclerosis (SSc).
|
29616048 |
2018 |
|
Systemic Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we show that the tumor necrosis factor (TNF) superfamily protein LIGHT (homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for binding to HVEM, a receptor expressed on T lymphocytes) is required for experimental atopic dermatitis, and LIGHT directly controls keratinocyte hyperplasia, and production of periostin, a matricellular protein that contributes to the clinical features of atopic dermatitis as well as other skin diseases such as scleroderma.
|
29339444 |
2018 |
|
Systemic Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Increased expression of the TNF superfamily member LIGHT/TNFSF14 and its receptors (HVEM and LTßR) in patients with systemic sclerosis.
|
30508197 |
2019 |
|
Leukemogenesis
|
0.030 |
Biomarker
|
disease |
BEFREE |
These data suggest that HVEM interaction with BTLA may play a role in lymphomagenesis by interfering with Vγ9Vδ2 T-cell proliferation.
|
23692853 |
2013 |
|
Leukemogenesis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Mutation-associated loss of this interaction promotes B cell proliferation through exaggerated T cell help, explaining how HVEM loss contributes to GC lymphomagenesis and revealing a cell-extrinsic tumor-suppressor role for BTLA.
|
31433965 |
2019 |
|
Leukemogenesis
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results establish that HVEM restrains the T helper signals delivered to B cells to influence GC selection outcomes, and they suggest that BTLA functions as a cell-extrinsic suppressor of GC B cell lymphomagenesis.
|
31204070 |
2019 |
|
Liver carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma.
|
25468715 |
2015 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the discovery cohort (n = 94), we found that lack of, or low, tumor expression of PD-L1 (<i>p</i> < 0.001), Galectin-9 (<i>p</i> < 0.001) and HVEM (<i>p</i> < 0.001), and low CD8<sup>+</sup>TIL count (<i>p</i> = 0.016), were associated with poor HCC-specific survival.
|
28344887 |
2017 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggested that the BTLA/HVEM pathway contributes to peripheral T cell suppression in HCC patients, and BTLA/HVEM may serve as attractive targets for HCC immunotherapy.
|
30116751 |
2018 |
|
Arthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, HVEM-Ig aggravates autoimmunity in collagen-induced arthritis, which is possibly mediated by interaction with B and T lymphocyte attenuator (BTLA) or CD160, despite the blockade of LIGHT.
|
19234211 |
2009 |